ABSTRACT
BACKGROUND: Pediatric oral hemangiomas are benign vascular tumors that can be seen from birth, particularly in females. Hemangiomas are most frequent located in the lips and usually regress spontaneously, thus they do not require any type of treatment in most cases. The present scoping review pretended to synthesize the most relevant and currently available information from the international dental literature published in the last 25 years, regarding the management of pediatric oral hemangiomas. MATERIAL AND METHODS: An exhaustive literature search was performed in four electronic databases (PubMed, Embase, Google Scholar, and Cochrane). Initially, 241 related titles and abstracts were found. After the duplication removal, screening, and assessment processes, 37 records were included for full-text reading. Finally, 20 articles in the English language were included in the scoping review for data extraction and assessment. RESULTS: We identified and subsequently discussed three fundamental issues associated to the management of pediatric oral hemangiomas: (I) clinical characteristics, differential diagnosis, and histopathological findings; (II) evolution and complications; and (III) current available treatment modalities. CONCLUSIONS: Although these like-tumor lesions are uncommon, pediatric dentistry practitioners must be familiar with the inherent clinical characteristics, diagnosis approaches, and currently available treatment options. Nowadays, surgical removal and non-invasive medical/pharmacologic therapies are the best management modalities for pediatric oral hemangiomas
No disponible
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Hemangioma/therapy , Mouth Neoplasms/therapy , Disease Management , Hemangioma/diagnosis , Mouth Neoplasms/diagnosis , Diagnosis, Differential , Pediatric DentistryABSTRACT
SUMMARY OBJECTIVE To present the results of metabolic control in patients with type 2 Diabetes Mellitus from a private clinic in Northern Mexico, METHODS This cross-sectional study used retrospective data obtained from electronic records from a private outpatient clinic at the end of 2018. Inclusion criteria were a diagnosis of T2DM and age ≥ 18 years. Baseline characteristics (age, gender, drug use) were reported. The achievement of glycated hemoglobin goals was established as <7%. RESULTS A total of 3820 patients were evaluated. Their mean age was 59.86 years (+/-15.01). Of the population, 46.72% were men, and 53.28% were women. Glycated hemoglobin goals were adequate in 1872 (54%) patients. There were 3247 patients (85%) treated with oral medications, of which 1948 (60%) reported glycated hemoglobin less than 7%. Insulin use was reported in 573 (15%) patients, with 115 (20%) reporting glycated hemoglobin less than 7%. The most frequently used basal insulin was glargine in 401 (70%) patients. CONCLUSIONS Our findings are clearly higher than the control rate reported by our national health surveys of 25% with glycated hemoglobin < 7%, but similar to that reported in other countries. The most commonly used therapeutic scheme was the combination of oral hypoglycemic agents. The percentage of cases that include insulin in their treatment was lower. Clinical inertia to insulin initiation and intensification has been defined as an important cause of this problem.
RESUMO OBJETIVO Apresentar os resultados do controle metabólico de pacientes com Diabetes Mellitus tipo 2 em uma clínica privada no norte do México, MÉTODOS Este estudo transversal utilizou dados retrospectivos obtidos em prontuários eletrônicos de um ambulatório privado no final de 2018. Os critérios de inclusão foram o diagnóstico de DM2 e idade ≥ 18 anos. Características basais (idade, sexo, uso de drogas) foram relatadas. A realização de metas de hemoglobina glicada foi estabelecida como <7%. RESULTADOS Um total de 3820 pacientes foram avaliados. A média de idade foi de 59,86 anos (+/- 15,01). Da população, 46,72% eram homens e 53,28% eram mulheres. Objetivos de hemoglobina glicada foram adequados em 1872 (54%) pacientes. Havia 3247 pacientes (85%) tratados com medicamentos orais relatando em 1948 (60%) menos de 7%. O uso de insulina foi relatado em 573 (15%) pacientes, com 115 (20%) relatando menos de 7%. A insulina basal mais utilizada foi a glargina, em 401 (70%) pacientes. CONCLUSÕES Nossos resultados são claramente mais altos do que a taxa de controle relatada por nossos levantamentos nacionais de saúde de 25% com hemoglobina glicada <7%, mas semelhante à relatada em outros países. O esquema terapêutico mais utilizado foi a combinação de hipoglicemiantes orais. A porcentagem de casos que incluem insulina no tratamento foi menor. A inércia clínica à iniciação e intensificação da insulina tem sido definida como uma importante causa desse problema.
Subject(s)
Humans , Male , Female , Adult , Aged , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Glycated Hemoglobin , Cross-Sectional Studies , Retrospective Studies , Drug Therapy, Combination , Insulin Glargine/administration & dosage , Mexico , Middle AgedABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant, Low Birth Weight , Fetal Macrosomia/epidemiology , Fetal Macrosomia/genetics , Metabolic Diseases/epidemiology , Cross-Sectional Studies , Mexico/epidemiology , Apgar ScoreABSTRACT
Fundamento y objetivo: Nuestro objetivo fue determinar la proporción de pacientes con diabetes mellitus tipo 2(DM2) con hipotiroidismo primario (HP) y compararlos con un grupo sin diabetes. Pacientes y métodos: Se revisó una base electrónica que incluyó 5.161 pacientes. Se identificaron los pacientes con DM2 tratados con levotiroxina. Se comparó con la prevalencia de HP en aquellos pacientes sin DM2. Se excluyeron enfermos con neoplasia o cirugía de tiroides, panhipopituitarismo o complicaciones quirúrgicas de bocio multinodular o nódulo tiroideo.Resultados: Se incluyeron 1.848 pacientes adultos con DM2 en el grupo de estudio, 58% mujeres y 42% hombres. Para el grupo control se revisaron 3.313 individuos, 55% mujeres y 45% hombres. La edad media del grupo de estudio fue de 52±7 años, y 47±4 años en el grupo control (p<0,001). La tasa de hipotiroidismo en el grupo de estudio fue de 5,7% (n=105) y en el grupo control 1,8% (n=60) (odds ratio 3,45; intervalo de confianza del 95% 2,51-4,79) (p<0,001).Conclusión: Existe una asociación significativa entre HP y DM2. Recomendamos el perfil tiroideo en todos los pacientes con DM2, similar a lo sugerido en la diabetes mellitus tipo 1 (AU)
Background and objective: The aim of our study was to identify the rate of diabetic patients treated for hypothyroidism and compare them with a group without type 2 diabetes mellitus (T2DM). Patients and methods: We reviewed the computerized clinical records of 5161 patients. We identified diabetic patients treated with l -thyroxine. We compared the prevalence of PH with those patients under treatment with levothyroxine without T2DM. We excluded patients with a thyroid neoplasia, thyroid surgery, panhypopituitarism, or surgical complications of multinodular goiter or a thyroid nodule. Subclinical hypothyroidism was not considered.Results: We included 1848 adult patients with T2DM in the study group, 58% women and 42% men. For the control group, we included 3313 non-diabetic patients, 55% women and 45% men. The mean age in the study group was 52±7 years, and 47±4 years in the control group (p<.001). The rate of hypothyroidism in the study group was 5.7%, and in the control group 1.8% (odds ratio of 3.45; 95% confidence interval 2.51-4.79) (p<.001). Conclusion: A strong association between T2DM and hypothyroidism was found. We recommend a thyroid profile in all patients with T2DM, similar to the recommendation in type 1 diabetes mellitus (AU)
Subject(s)
Humans , Hypothyroidism/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Risk Factors , Cardiovascular Diseases/epidemiology , Thyroid Function TestsABSTRACT
OBJECTIVE: Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development. METHODS: Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation. RESULTS: 50 patients were included, predominantly women (66 percent, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68 percent, 94 percent and 98 percent, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables. CONCLUSION: Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.
OBJETIVO: Pulsos de metilprednisolona são usados em diversas doenças, tanto para tratamento agudo quanto crônico. Embora bem tolerados, eles aumentam os níveis de glicose em ambos os pacientes, não diabéticos e diabéticos. Eles também podem ser considerados um risco significativo para alterações metabólicas agudas. O propósito deste estudo é determinar as alterações metabólicas nos níveis de glicose no sangue de pacientes não diabéticos que recebem pulsos de metilprednisolona e identificar a presença de fatores preditivos para seu desenvolvimento. MÉTODOS: Estudo observacional prospectivo em 50 pacientes não diabéticos que recebem pulsoterapia com 1 g de metilprednisolona intravenosa por três dias consecutivos como tratamento para diversas doenças autoimunes. Variáveis demográficas, antropométricas e metabólicas foram analisadas, e glicose, insulina e níveis de peptídeo C foram identificados após cada pulso de esteroide. Diferentes variáveis e a magnitude da hiperglicemia foram analisadas utilizando a correlação de Pearson. RESULTADOS: 50 pacientes foram incluídos, predominantemente mulheres (66 por cento, n = 33). A idade média foi de 41 ± 14 anos com um IMC de 26 ± 3 kg/m². A glicose de base foi de 83 ± 10 mg/dL. Após cada pulso de esteroide, a glicose aumentou para 140 ± 28, 160 ± 38 e 183 ± 44, respectivamente (p < 0,001). Peptídeo C e concentrações de insulina aumentaram significativamente (p < 0,001). A prevalência de hiperglicemia em jejum após cada pulso foi de 68 por cento, 94 por cento e 98 por cento, respectivamente. Não encontramos nenhuma correlação entre a magnitude da hiperglicemia e as variáveis estudadas. CONCLUSÃO: Os pulsos de metilprednisolona produziram aumentos significativos na glicemia de jejum na maioria dos pacientes sem diabetes. Mais estudos são necessários para definir o seu papel nas consequências em longo prazo.
Subject(s)
Adolescent , Adult , Female , Humans , Male , Blood Glucose/drug effects , Glucocorticoids/adverse effects , Hyperglycemia/chemically induced , Methylprednisolone/adverse effects , Blood Glucose/metabolism , Hyperglycemia/metabolism , Mexico , Prospective Studies , Pulse Therapy, Drug , Risk FactorsABSTRACT
Introducción. La fenilcetonuria es un padecimiento que puede diagnosticarse oportunamente, sin embargo, aún es posible detectar pacientes con secuelas neurológicas graves que desafortunadamente no fueron sujetos a un estudio al nacimiento. Casos clínicos. El primer caso se trató de una paciente de 12 meses que acudió por retardo en el desarrollo psicomotor, sus niveles de fenilalanina en sangre fueron de 1 285 μmol/L (normal 31-75 μmol/L). Su hermana mayor (caso 2) mostraba retardo en el desarrollo psicomotor considerado secundario a secuelas de encefalopatía hipóxico-isquémica, sin embargo también mostró hiperfenilalaninemia. El caso 3 se trató de una niña de 10 años que acudió por retardo psicomotor e hiperactividad; presentó ansiedad, irritabilidad, microcefalia, cabello rubio y piel clara. Los niveles de fenilalanina fueron de 1 170 μmol/L. En todos los casos se inició dieta baja en fenilalanina y después de un mes los niveles disminuyeron a la mitad. Actualmente mantienen valores normales de fenilalanina y muestran mejoría neurológica notable. Conclusión. La intervención nutricional puede revertir algunas secuelas neurológicas en los casos con diagnóstico tardío de fenilcetonuria.
Introduction. Phenylketonuria is a genetic disease that can be diagnosed easily and treated promptly avoiding long-term disabilities. Nevertheless, some children still lack neonatal screening as well as appropriate diagnosis, and they may present serious irreversible neurological damage. Case report. We report 3 cases. Case 1 is a 12 month-old female with motor and developmental delay. Phenylalanine levéis were 1 285 μmol/L (normal values 31-75 μmol/L). Her sister (case 2) was a 6 year-old mentally retarded child previously thought to be due to hypoxic-ischemic encephalopathy; her phenylalanine levéis were 1 729 μmol/L. Case 3 describes a 10 year-old female with developmental delay, hyperactivity, anxiety, irritability, microcephaly, light-colored hair, and white skin. Phenylalanine levéis were 1170 μmol/L. A low-phenylalanine diet was prescribed for each patient. One month later they were evaluated and showed significantly reduced phenylalanine levéis (50%). Currently, they maintain normal values and show im-portant physical and neurological improvement. Conclusions. In cases of late-diagnosed phenylketonuria, a prompt treatment with a strict nutritional management may revert some of the neurological damage developed in these patients.
ABSTRACT
OBJETIVO: Instituir un programa estatal de tamizaje neonatal ampliado para identificar errores innatos del metabolismo y determinar su prevalencia en la población de recién nacidos del estado de Nuevo León. MATERIAL Y MÉTODOS: Entre marzo de 2002 y febrero de 2004 se incluyeron neonatos consecutivos nacidos en hospitales públicos del estado. Se colectaron muestras de sangre en papel filtro entre las 24 y 48 horas de vida y se las sometió a tamiz metabólico mediante espectrometría de masas en tándem. RESULTADOS: Se analizaron 42 264 primeras muestras y se detectaron siete casos, uno de cada padecimiento: homocistinuria, fenilcetonuria, citrulinemia, tirosinemia/transitoria, deficiencia de 3-metilcrotonil-CoA carboxilasa, deficiencia de 3-hidroxi-3-metilglutaril-CoA liasa y galactosemia típica. CONCLUSIONES: La incidencia acumulada de defectos metabólicos en la población fue de 1:5 000 con 0.22 por ciento de casos falso-positivos. El programa permitió identificar y tratar con oportunidad los trastornos metabólicos al nacimiento con una efectiva prevención secundaria del retraso mental.
OBJECTIVE: To initiate a statewide expanded metabolic screening program in neonates with the purpose of identifying the most common inborn errors of metabolism. MATERIAL AND METHODS: From March 2002 through February 2004, a blood sample was obtained between 24 and 48 hours after delivery from every consecutive child born in public hospitals in Nuevo León. It was spotted on filter paper and analyzed by tandem mass spectrometry for expanded metabolic screening. RESULTS: A total of 42 264 samples were analyzed. Were obtained seven positive results, one for each disorder: homocystinuria, hyperphenylalaninemia, citrulinemia, transient tyrosinemia, 3-methylcrotonyl CoA carboxylase deficiency, 3-hydroxy-3-methylglutaryl CoA deficiency, and classic galactosemia. CONCLUSIONS: The estimated incidence of inborn errors of metabolism is 1:5 000, with a false positive rate of 0.22 percent. The program permitted the identification of metabolic disorders in the newborn, allowing an early intervention and prevention of life-threatening events and permanent neurological damage.
Subject(s)
Humans , Infant, Newborn , Metabolism, Inborn Errors/diagnosis , Neonatal Screening , Tandem Mass Spectrometry , Mexico , Neonatal Screening/methods , Time FactorsABSTRACT
Se evaluó el estado nutricional de 360 adultos que consultaron los ambulatorios "Don Pedro del Corral", "Araguaney" y las Clínicas Móviles, entre abril y junio de 2005, para el diagnóstico de obesidad, la cual se determinó según el índice de masa corporal sugerido por la Organización Mundial de la Salud (OMS) y se clasificó la obesidad en tipo I, tipo II y tipo III según la OMS. 28,88 por ciento de los pacientes femeninos que consultaron presentaron obesidad y 23,33 por ciento de los pacientes masculinos fueron obesos. Hubo obesidad de tipo I en un 65,79 por ciento, de tipo II en un 23,68 por ciento y de tipo III en un 10,52 por ciento. Los datos obtenidos fueron significativamente superiores a los datos publicados internacionalmente en Europa, Estados Unidos y el resto de Latinoamérica.
Subject(s)
Humans , Male , Adult , Female , Body Weight , Nutritional Status , ObesityABSTRACT
La violencia de género tiene lugar en casi todas las culturas y en todas las escalas sociales y la mayoría de las veces ocurre en el hogar. Se trata de un problema de salud pública debido al impacto negativo que ejerce sobre la salud, la morbilidad y la mortalidad de las mujeres. Se desciben tres casos de violencia doméstica durante el embarazo atendidos en el Hospital Universtario de Caracas entre 1997 y 2002